Skip to main content
. 2022 Nov 8;328(18):1864–1866. doi: 10.1001/jama.2022.14847

Table 2. Trends by Biomarker of Exposure for Smokers, Nonnicotine Vapers (NNVs), and Nicotine Vapers (NVs), 2013-2019a.

Wave 1 (Sep 2013 to Dec 2014) Wave 2 (Oct 2014 to Oct 2015) Wave 3 (Oct 2015 to Oct 2016) Wave 4 (Oct 2016 to Jan 2018) Wave 5 (Dec 2018 to Nov 2019) P value for within-group linear trendb
Total nicotine equivalents, mean (95% CI), nmol/mg of creatinine c
Smokers 27.3 (24.1-30.9) 29.6 (27.0-32.5) 32.8 (29.4-36.7) 29.5 (26.2-33.2) 30.8 (26.5-35.7) .34
NNVs 0.8 (0.2-3.1) 0.2 (0-0.8) 0.2 (0.1-0.6) 0.2 (0.1-0.5) 0.2 (0.1-0.6) .29
NVs 11.0 (7.2-16.7) 14.3 (9.5-21.7) 18.9 (13.9-25.7) 19.4 (14.4-26.2) 21.8 (15.2-31.4) .001
Smokers vs NNVsd 33.7 (9.0-126.5) 168.9 (39.4-723.6) 165.7 (52.4-524.2) 173.0 (56.6-528.5) 149.9 (47.4-474.0)
P valuee <.001 <.001 <.001 <.001 <.001
NVs vs NNVsd 13.5 (3.7-50.0) 81.9 (17.9-374.7) 95.2 (29.3-309.9) 113.9 (36.9-351.4) 106.3 (33.5-337.3)
P valuee <.001 <.001 <.001 <.001 <.001
Smokers vs NVsd 2.5 (1.6-3.8) 2.1 (1.4-3.1) 1.7 (1.3-2.4) 1.5 (1.1-2.1) 1.4 (0.9-2.1)
P valuee <.001 .004 .007 .07 .32
Cotinine, mean (95% CI), ng/mg of creatinine f
Smokers 1750.1 (1551.6-1974.0) 1888.6 (1729.7-2062.1) 2109.3 (1882.3-2363.6) 1868.0 (1659.7-2102.4) 2002.0 (1724.8-2323.8) .17
NNVs 49.9 (12.3-203.2) 9.9 (2.3-42.5) 11.2 (3.6-34.5) 11.1 (3.5-34.6) 12.2 (4.2-35.8) .35
NVs 709.0 (454.0-1107.3) 965.4 (627.7-1484.6) 1186.8 (865.3-1627.8) 1226.1 (890.7-1687.9) 1416.6 (993.7-2019.4) .002
Smokers vs NNVsd 35.1 (8.8-139.9) 191.4 (44.8-818.1) 188.4 (60.7-585.2) 168.5 (53.5-529.7) 164.3 (55.0-490.6)
P valuee <.001 <.001 <.001 <.001 <.001
NVs vs NNVsd 14.2 (3.5-57.1) 97.8 (21.4-446.3) 106.0 (33.2-338.6) 110.6 (34.8-351.5) 116.2 (38.7-349.3)
P valuee .001 <.001 <.001 <.001 <.001
Smokers vs NVsd 2.5 (1.6-3.9) 2.0 (1.3-3.0) 1.8 (1.3-2.5) 1.5 (1.1-2.1) 1.4 (1.0-2.1)
P valuee <.001 .008 .003 .06 .22
Tobacco-specific nitrosamine: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), mean (95% CI), pg/mg of creatinine g
Smokers 197.4 (180.2-216.2) 204.2 (188.2-221.5) 235.4 (216.1-256.3) 218.3 (197.4-241.3) .07
NNVs 10.1 (4.9-20.9) 3.3 (1.3-8.5) 3.9 (2.4-6.3) 3.8 (1.9-7.5) .16
NVs 6.3 (4.9-8.3) 5.9 (4.6-7.7) 4.9 (4.0-5.9) 5.1 (3.9-6.6) .14
Smokers vs NNVsd 19.5 (9.6-39.8) 62.4 (24.0-162.6) 60.6 (37.6-97.7) 57.5 (28.7-115.1)
P valuee <.001 <.001 <.001 <.001
NVs vs NNVsd 0.6 (0.3-1.4) 1.8 (0.7-4.9) 1.2 (0.7-2.1) 1.3 (0.7-2.7)
P valuee .33 .13 .50 .24
Smokers vs NVsd 31.1 (23.8-40.7) 34.4 (26.4-44.8) 48.5 (38.6-61.0) 43.0 (32.8-56.3)
P valuee <.001 <.001 <.001 <.001
a

Urine biospecimens were collected in person from a stratified probability sample of wave 1 adults who provided a sufficient urine sample and were selected from a diverse mix of 6 tobacco product use groups representing never, current, and recent former (within 12 months) users of tobacco products. Biomarker concentrations below the limit of detection were imputed using a standard substitution formula (limit of detection/√2).

b

Wave served as the predictor and age, sex, race and ethnicity, and education served as covariates; for NNVs and NVs, there was further adjustment for e-cigarette device types and number of recent puffs. For the wave × group interaction P values, a linear regression model omnibus interaction test adjusted for age, sex, race and ethnicity, and education.

c

P= .003 for wave × group interaction. Total nicotine equivalents is the molar sum of the imputed values of cotinine and trans-3′-hydroxycotinine in urine.

d

The data are expressed as the ratio of means (95% CI) for the pairwise between-group comparisons.

e

From multivariable regressions adjusted for age, sex, race and ethnicity, and education.

f

P= .005 for wave × group interaction.

g

P= .06 for wave × group interaction.